CN1646172A - 包含喜树碱衍生物的液体制剂以及冻干该制剂制得的药物组合物 - Google Patents
包含喜树碱衍生物的液体制剂以及冻干该制剂制得的药物组合物 Download PDFInfo
- Publication number
- CN1646172A CN1646172A CNA038082292A CN03808229A CN1646172A CN 1646172 A CN1646172 A CN 1646172A CN A038082292 A CNA038082292 A CN A038082292A CN 03808229 A CN03808229 A CN 03808229A CN 1646172 A CN1646172 A CN 1646172A
- Authority
- CN
- China
- Prior art keywords
- liquid preparation
- gly
- glycyl
- preparation
- camptothecin derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
比较例 | 本发明的液体制剂 | ||||
1 | 2 | 3 | 4 | ||
药物(g) | 0.4 | ||||
磷酸二氢钠(g) | 0.110 | 0.147 | 0.180 | 0.213 | 0.245 |
柠檬酸 | 0.118 | 0.093 | 0.071 | 0.047 | 0.023 |
0.4M的磷酸二氢钠水溶液 | q.s. | q.s. | |||
0.2M的柠檬酸水溶液 | q.s. | q.s. | |||
氯化钠(g) | 0.771 | 0.771 | |||
注射用水 | q.s. | q.s. | |||
总共 | 100mL | 100mL | |||
Ph | 4.0 | 5.0 | 6.0 | 7.0 | 8.0 |
pH | 保存条件 | 平均分子量 | 平均分子量分布 | |
本发明的液体制剂1 | 5.0 | 开始 | 138,900 | 1.195 |
60℃ 20天 | 125,800 | 1.183 | ||
本发明的液体制剂2 | 6.0 | 开始 | 129,100 | 1.169 |
60℃ 20天 | 131,200 | 1.177 | ||
本发明的液体制剂3 | 7.0 | 开始 | 131,400 | 1.191 |
60℃ 20天 | 131,400 | 1.186 | ||
本发明的液体制剂4 | 8.0 | 开始 | 130,900 | 1.202 |
60℃ 20天 | 127,000 | 1.195 | ||
比较例 | 4.0 | 开始 | 129,800 | 1.200 |
60℃ 20天 | 110,100 | 1.720 |
pH | 游离活性喜树碱化合物的量(%)* | ||||
开始 | 60℃ 20天 | 50℃ 30天 | 40℃ 120天 | ||
本发明的液体制剂1 | 5.0 | 3.08 | 13.15 | 9.17 | 10.60 |
本发明的液体制剂2 | 6.0 | 1.67 | 8.12 | 5.83 | 5.53 |
本发明的液体制剂3 | 7.0 | 1.48 | 14.53 | 6.60 | 6.52 |
本发明的液体制剂4 | 8.0 | 1.93 | 17.32 | 8.31 | 7.95 |
比较例 | 4.0 | 13.81 | 23.73 | 24.84 | 27.33 |
比较例 | 本发明的组合物 | |||||
A | B | 1 | 2 | 3 | 4 | |
药物(g) | 5.0 | |||||
磷酸二氢钠溶液(g) | 0.0059 | 0.110 | 0.147 | 0.180 | 0.213 | 0.245 |
柠檬酸 | 0.153 | 0.118 | 0.093 | 0.071 | 0.047 | 0.023 |
0.4M的磷酸二氢钠水溶液 | q.s. | q.s. | ||||
0.2M的柠檬酸水溶液 | q.s. | q.s. | ||||
注射用水 | q.s. | q.s. | ||||
总共 | 100mL | 100mL | ||||
pH | 3.0 | 4.0 | 5.0 | 6.0 | 7.0 | 8.0 |
比较例 | 本发明的组合物 | |||||
A | B | 1 | 2 | 3 | 4 | |
颜色改变 | 无(黄色) | 无(淡黄绿色) | 无(淡黄绿色) | |||
再构以后的状态 | 不溶物:有 | 不溶物:少量 | 不溶物:无 | |||
再构以后的pH | 3.0 | 4.1 | 5.1 | 6.1 | 7.1 | 8.1 |
pH | 保存条件 | 平均分子量 | 平均分子量分布 | |
本发明的组合物1 | 5.0 | 开始 | 135,400 | 1.144 |
60℃ 20天 | 128,700 | 1.145 | ||
本发明的组合物2 | 6.0 | 开始 | 132,800 | 1.145 |
60℃ 20天 | 128,500 | 1.140 | ||
本发明的组合物3 | 7.0 | 开始 | 130,600 | 1.143 |
6℃ 20天 | 128,300 | 1.147 | ||
本发明的组合物4 | 8.0 | 开始 | 129,800 | 1.144 |
60℃ 20天 | 131,100 | 1.128 | ||
比较例A | 3.0 | 开始 | 132,900 | 1.120 |
60℃ 20天 | 150,300 | 1.280 | ||
比较例B | 4.0 | 开始 | 135,100 | 1.134 |
60℃ 20天 | 138,100 | 1.209 |
pH | 游离活性化合物的量(%)(保存条件:60℃ 20天) | |
本发明的组合物1 | 5.0 | <0.3 |
本发明的组合物2 | 6.0 | <0.3 |
本发明的组合物3 | 7.0 | <0.3 |
本发明的组合物4 | 8.0 | <0.3 |
比较例A | 3.0 | 0.76 |
比较例B | 4.0 | 0.48 |
每100个安瓿的破损数量 | |
本发明的冻干组合物 | 0 |
比较例的冻干组合物 | 40 |
Claims (15)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP1128642002 | 2002-04-16 | ||
JP2002112864 | 2002-04-16 | ||
JP112864/2002 | 2002-04-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1646172A true CN1646172A (zh) | 2005-07-27 |
CN100544769C CN100544769C (zh) | 2009-09-30 |
Family
ID=29243336
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB038082292A Expired - Fee Related CN100544769C (zh) | 2002-04-16 | 2003-04-15 | 包含喜树碱衍生物的液体制剂以及冻干该制剂制得的药物组合物 |
Country Status (21)
Country | Link |
---|---|
US (1) | US20050215485A1 (zh) |
EP (1) | EP1501549A2 (zh) |
JP (1) | JP3927954B2 (zh) |
KR (1) | KR100700963B1 (zh) |
CN (1) | CN100544769C (zh) |
AR (1) | AR039272A1 (zh) |
AU (1) | AU2003223120B2 (zh) |
BR (1) | BR0309283A (zh) |
CA (1) | CA2480425A1 (zh) |
HR (1) | HRP20040894A2 (zh) |
ME (1) | MEP31308A (zh) |
MX (1) | MXPA04010178A (zh) |
MY (1) | MY136696A (zh) |
NO (1) | NO20044964L (zh) |
PL (1) | PL371677A1 (zh) |
RS (1) | RS91204A (zh) |
RU (1) | RU2315623C2 (zh) |
TW (1) | TW200306314A (zh) |
UA (1) | UA77295C2 (zh) |
WO (1) | WO2003086471A2 (zh) |
ZA (1) | ZA200408008B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102764260A (zh) * | 2011-04-30 | 2012-11-07 | 江苏正大天晴药业股份有限公司 | 一种喜树碱衍生物的药物组合物及其制备方法 |
CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602005024923D1 (de) * | 2004-02-13 | 2011-01-05 | Yakult Honsha Kk | Wässrige lösung mit einem camptothecin |
CN1946421B (zh) | 2004-04-27 | 2013-07-17 | 威尔斯达特生物制剂公司 | 使用病毒和喜树碱进行的癌症治疗 |
RU2435586C2 (ru) | 2005-07-14 | 2011-12-10 | Веллстат Байолоджикс Корпорейшн | Лечение рака с применением вирусов, фторпиримидинов и камптотецинов |
JP2007260275A (ja) * | 2006-03-29 | 2007-10-11 | Transcutaneous Technologies Inc | イオントフォレーシス装置及びイオントフォレーシス投与用組成物 |
WO2010151544A1 (en) | 2009-06-22 | 2010-12-29 | Wyeth Llc | Immunogenic compositions of staphylococcus aureus antigens |
JP2012530785A (ja) | 2009-06-22 | 2012-12-06 | ワイス・エルエルシー | 組成物および黄色ブドウ球菌(Staphylococcusaureus)血清型5および8莢膜多糖コンジュゲート免疫原性組成物を調製するための方法 |
WO2013011598A1 (ja) * | 2011-07-15 | 2013-01-24 | コニカミノルタホールディングス株式会社 | 溶解助剤を利用したリポソーム含有製剤およびその製造方法 |
AU2015369185B2 (en) | 2014-12-26 | 2020-10-22 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical preparation of camptothecin-containing polymer derivative |
KR20180039628A (ko) | 2015-09-03 | 2018-04-18 | 니폰 가야꾸 가부시끼가이샤 | 캄프토테신류 고분자 유도체를 함유하는 의약 조성물 |
AU2016326747A1 (en) | 2015-09-25 | 2018-03-01 | Zy Therapeutics Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
CN108697806A (zh) * | 2016-03-01 | 2018-10-23 | 日本化药株式会社 | 含有喜树碱类高分子衍生物的药物制剂 |
AU2022396967A1 (en) * | 2021-11-26 | 2024-06-13 | Astellas Pharma Inc. | Indocyanine compound-containing solid pharmaceutical composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5340817A (en) * | 1987-04-14 | 1994-08-23 | Research Triangle Institute | Method of treating tumors with anti-tumor effective camptothecin compounds |
SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
AR030207A1 (es) * | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
AU2001271037A1 (en) * | 2000-07-13 | 2002-01-30 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compounds |
TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
-
2003
- 2003-04-01 TW TW092107354A patent/TW200306314A/zh unknown
- 2003-04-09 AR ARP030101238A patent/AR039272A1/es unknown
- 2003-04-11 MY MYPI20031367A patent/MY136696A/en unknown
- 2003-04-15 AU AU2003223120A patent/AU2003223120B2/en not_active Ceased
- 2003-04-15 PL PL03371677A patent/PL371677A1/xx not_active Application Discontinuation
- 2003-04-15 BR BR0309283-6A patent/BR0309283A/pt not_active IP Right Cessation
- 2003-04-15 JP JP2003587152A patent/JP3927954B2/ja not_active Expired - Fee Related
- 2003-04-15 MX MXPA04010178A patent/MXPA04010178A/es active IP Right Grant
- 2003-04-15 CA CA002480425A patent/CA2480425A1/en not_active Abandoned
- 2003-04-15 US US10/509,912 patent/US20050215485A1/en not_active Abandoned
- 2003-04-15 WO PCT/JP2003/004745 patent/WO2003086471A2/en active Application Filing
- 2003-04-15 CN CNB038082292A patent/CN100544769C/zh not_active Expired - Fee Related
- 2003-04-15 ME MEP-313/08A patent/MEP31308A/xx unknown
- 2003-04-15 RS YU91204A patent/RS91204A/sr unknown
- 2003-04-15 RU RU2004133349/15A patent/RU2315623C2/ru not_active IP Right Cessation
- 2003-04-15 KR KR1020047016514A patent/KR100700963B1/ko not_active IP Right Cessation
- 2003-04-15 UA UA20041109367A patent/UA77295C2/uk unknown
- 2003-04-15 EP EP03719110A patent/EP1501549A2/en not_active Withdrawn
-
2004
- 2004-09-29 HR HR20040894A patent/HRP20040894A2/xx not_active Application Discontinuation
- 2004-10-05 ZA ZA200408008A patent/ZA200408008B/en unknown
- 2004-11-15 NO NO20044964A patent/NO20044964L/no not_active Application Discontinuation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102764260A (zh) * | 2011-04-30 | 2012-11-07 | 江苏正大天晴药业股份有限公司 | 一种喜树碱衍生物的药物组合物及其制备方法 |
CN102764260B (zh) * | 2011-04-30 | 2014-07-30 | 正大天晴药业集团股份有限公司 | 一种喜树碱衍生物的药物组合物及其制备方法 |
CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
Also Published As
Publication number | Publication date |
---|---|
MY136696A (en) | 2008-11-28 |
CA2480425A1 (en) | 2003-10-23 |
RU2004133349A (ru) | 2005-05-27 |
AU2003223120A1 (en) | 2003-10-27 |
AR039272A1 (es) | 2005-02-16 |
BR0309283A (pt) | 2005-02-15 |
JP3927954B2 (ja) | 2007-06-13 |
MEP31308A (en) | 2010-10-10 |
NO20044964L (no) | 2004-11-15 |
RU2315623C2 (ru) | 2008-01-27 |
KR20050000516A (ko) | 2005-01-05 |
US20050215485A1 (en) | 2005-09-29 |
AU2003223120B2 (en) | 2006-10-05 |
PL371677A1 (en) | 2005-06-27 |
EP1501549A2 (en) | 2005-02-02 |
TW200306314A (en) | 2003-11-16 |
ZA200408008B (en) | 2005-06-13 |
KR100700963B1 (ko) | 2007-03-28 |
AU2003223120A2 (en) | 2003-10-27 |
RS91204A (en) | 2006-12-15 |
JP2005523329A (ja) | 2005-08-04 |
WO2003086471A3 (en) | 2004-04-15 |
WO2003086471A2 (en) | 2003-10-23 |
MXPA04010178A (es) | 2005-06-08 |
CN100544769C (zh) | 2009-09-30 |
HRP20040894A2 (en) | 2005-10-31 |
UA77295C2 (en) | 2006-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8518893B2 (en) | Medical compositions containing ghrelin | |
CN1130223C (zh) | 包含生长激素,氨基酸和非离子去污剂的药物配方 | |
CN1646172A (zh) | 包含喜树碱衍生物的液体制剂以及冻干该制剂制得的药物组合物 | |
JP5599778B2 (ja) | 液体緩衝gdf−5製剤 | |
EP0895784B1 (en) | Drug complexes comprising taxane compounds or steroids | |
KR20040074099A (ko) | Egf 수용체에 대한 항체를 함유하는 동결건조된 제제 | |
JP2006137678A (ja) | インターロイキン−2組成物 | |
CN1761485A (zh) | 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂 | |
WO2016047797A1 (ja) | 注射用医薬組成物 | |
CN1449292A (zh) | 长期稳定溶液制剂 | |
CN1662250A (zh) | 包含寡肽和醚化环糊精的液体制剂 | |
CN1684703A (zh) | 持续释放的药物活性肽施用形式及其制备方法 | |
JP6285447B2 (ja) | 経口ペプチド送達用の脂肪酸アシル化d−アミノ酸 | |
CN114126584A (zh) | 重组蛋白质稳定制剂 | |
WO2014102731A1 (en) | Novel pharmaceutical compositions of romidepsin | |
CN110152011B (zh) | 一种免疫调节因子与紫杉烷的共价链接物及其白蛋白纳米制剂 | |
JPWO2016080367A1 (ja) | 安定化されたペプチド組成物 | |
JP2016079187A (ja) | 懸濁液剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TANABE MITSUBISHI PHARMACEUTICAL CO. Free format text: FORMER OWNER: TANADE SEIYAKU CO., LTD. Effective date: 20071207 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20071207 Address after: Osaka Japan Applicant after: Mitsubishi Tanabe Pharma Corporation Address before: Osaka Japan Applicant before: Tanabe Seiyaku Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090930 Termination date: 20110415 |